Abstract
The art and science of drug discovery and development exist on a continuum that often requires an average of about 8 to 12 years to complete (Fig. 1). According to Peter Grandsard, Ph.D., of Amgen, the 2004 ALA president and associate program chair for ALA LabFusion 2004, for the past 10 years or so, most laboratory automation efforts have focused on the early stages of the process of therapeutic discovery and development. Says Dr. Grandsard, ‘‘The target discovery and high-throughput screening for small molecule hits or binding antibodies were logically the first to incorporate new technology to get more done in a shorter period of time. Expanding and speeding up hit-to-lead operations followed soon. These high-throughput functions are still
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: JALA: Journal of the Association for Laboratory Automation
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
